

## Overview

### Useful For

Monitoring for appropriate therapeutic concentration of phenobarbital

Assessing compliance or toxicity

### Method Name

Kinetic Interaction of Microparticles in a Solution (KIMS)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Specimen Required

#### Collection Container/Tube:

**Preferred:** Serum gel

**Acceptable:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 0.5 mL

#### Collection Instructions:

1. Serum gel tubes should be centrifuged within 2 hours of collection.
2. Red-top tubes should be centrifuged, and the serum aliquoted into a plastic vial within 2 hours of collection.

### Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

[-Neurology Specialty Testing Client Test Request \(T732\)](#)

[-Therapeutics Test Request \(T831\)](#)

### Specimen Minimum Volume

0.25 mL

### Reject Due To

Gross hemolysis	Reject
-----------------	--------

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum	Ambient	72 hours	
	Refrigerated (preferred)	7 days	
	Frozen	28 days	

**Clinical & Interpretive****Clinical Information**

Phenobarbital is a general central nervous system (CNS) suppressant that has proven effective in the control of generalized and partial seizures. It is frequently coadministered with phenytoin for control of complex seizure disorders and with valproic acid for complex parietal seizures.

Phenobarbital is administered in doses of 60 to 300 mg/day in adults or 3 to 6 mg/kg/day in children.

Phenobarbital is slowly but completely absorbed, with bioavailability in the range of 100%. It is approximately 50% protein bound with a volume of distribution of 0.5 L/kg. Phenobarbital has a long half-life of 96 hours, with no known active metabolites.

Sedation is common at therapeutic concentrations for the first 2 to 3 weeks of therapy, but this side effect disappears with time.

Toxicity due to phenobarbital overdose is characterized by CNS sedation and reduced respiratory function. Mild symptoms characterized by ataxia, nystagmus, fatigue, or attention loss, occur at blood concentrations above 40.0 mcg/mL. Symptoms become severe at concentrations of 60.0 mcg/mL and higher. Toxicity becomes life-threatening at concentrations over 100.0 mcg/mL. Death usually occurs due to respiratory arrest when pulmonary support is not supplied manually.

There are no known drug interactions that significantly affect the pharmacokinetics of phenobarbital; conversely, phenobarbital affects the pharmacokinetics of other drugs significantly because it induces the synthesis of enzymes associated with the hepatic cytochrome P450 metabolic pathway.

Acute intermittent porphyria attacks may be induced by phenobarbital stimulation of hepatic cytochrome P450.

**Reference Values****Interpretation**

Clinical response to the drug correlates strongly with blood concentration.

Dosage adjustments are made after 2 weeks of therapy to achieve steady-state blood levels in the range of 20.0 to 40.0 mcg/mL for adults; 15.0 to 30.0 mcg/mL for infants and children.

---

Patients chronically administered phenobarbital usually do not experience sedation unless the blood concentration is above 40.0 mcg/mL.

**Cautions**

No significant cautionary statements

**Clinical Reference**

Foero O, Kastrup KW, Nielsen EL, et al: Successful prophylaxis of febrile convulsions with phenobarbital. *Epilepsia* 1972;13:279-285

**Performance****Method Description**

The assay is based on the kinetic interaction of microparticles in a solution (KIMS). Phenobarbital antibody is covalently coupled to microparticles and the drug derivative is linked to a macromolecule. The kinetic interaction of microparticles in solutions is induced by binding of drug-conjugate to the antibody on the microparticles and is inhibited by the presence of phenobarbital in the sample. A competitive reaction takes place between the drug conjugate and phenobarbital in the serum sample for binding to the phenobarbital antibody on the microparticles. The resulting kinetic interaction of microparticles is indirectly proportional to the amount of drug present in the sample. (Package insert: Roche Phenobarbital reagent, Roche Diagnostic Corp, Indianapolis, IN)

**PDF Report**

No

**Day(s) Performed**

Monday through Sunday

**Report Available**

Same day/1 day

**Specimen Retention Time**

1 week

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.

- 
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

**CPT Code Information**

80184

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
PBR	Phenobarbital, S	3948-7

Result ID	Test Result Name	Result LOINC® Value
PBR	Phenobarbital, S	3948-7